Viking Therapeutics Faces Pivotal Summer for Its Obesity Drug Pipeline

The race to capture a share of the multi-billion dollar weight-loss drug market is intensifying. Viking Therapeutics, positioning itself with a distinct strategy against larger pharmaceutical incumbents, approaches a critical period. Two major clinical milestones scheduled for the third quarter of this year could fundamentally shape the future of its obesity treatment candidate and the company's trajectory.

Financial Backing and Market Sentiment

Currently valued at approximately $3.8 billion on the stock market, Viking Therapeutics enjoys a solid financial foundation for its upcoming endeavors. The company's balance sheet shows cash reserves significantly exceeding its debt, providing ample funding for the expensive late-stage clinical trials ahead. Despite shares trading around $33, below their 52-week high, analyst sentiment remains notably bullish ahead of the summer data readouts. Prominent Wall Street firms have issued price targets indicating substantial upside potential:

• Raymond James: $118 (Strong Buy)
• Jefferies: $101
• Morgan Stanley: $99 (Overweight)

A Dual-Phase Strategy with VK2735

At the core of Viking's strategy is its drug candidate, VK2735. The company is pursuing an approach that differentiates it from several established competitors: it aims to use the exact same molecule for both the initial weight reduction phase and the subsequent long-term maintenance phase for patients. This streamlined method is designed to simplify treatment regimens and potentially improve patient adherence.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

This summer, the market anticipates results from a specific study testing various administration methods and dosages of VK2735, ranging from monthly injections to daily or weekly oral tablets. Concurrently, management is preparing to initiate the crucial Phase 3 clinical trial for the oral formulation of VK2735, with this milestone also slated for Q3.

The Stakes and the Oral Tablet Opportunity

The coming months through autumn will be decisive for VK2735's commercial prospects. Should the clinical studies fail to meet their objectives, the setback would impact Viking's entire development pipeline. Conversely, positive data would pave the way for an accelerated regulatory pathway, even before the final results from the large VANQUISH program are available in 2027.

The oral tablet version represents a significant growth opportunity. Pills are widely seen as the next major driver in the metabolic disease market, which is projected to reach an estimated $100 billion by 2030. Offering a patient-friendly alternative to the current standard of injections, an effective oral therapy could substantially shift prescribing and patient preferences, capturing a large market segment.

Ad

Viking Therapeutics Stock: New Analysis - 29 March

Fresh Viking Therapeutics information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Viking Therapeutics analysis...

US92686J1060 | VIKING | boerse | 69020231 |